Top U.S. LASIK Surgeon Supports Presbia’s Microlens as Solution to Near-Vision

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that top U.S. LASIK surgeon Dr. Kerry Assil strongly supports the Presbia Flexivue Microlens™ as an excellent treatment for presbyopia, the loss of near-vision. The Presbia Flexivue Microlens is an innovative solution for presbyopia, which substitutes a proprietary optical lens implant for the requirement to wear reading glasses. Dr. Assil spoke with Jefferies, the global investment banking firm on a May 10, 2016 investor call discussing the broad topic of presbyopia-treating technologies and corneal inlay technologies.

Dr. Assil, an ophthalmologist and refractive surgeon, has been practicing refractive surgery for more than 25 years and has performed more than 50,000 refractive surgery procedures including corneal inlays, LASIK, intra ocular procedures, cataracts and refractive lens exchanges.

Dr. Assil commented that nearly everyone over 40 years old develops presbyopia, and for those seeking a surgical solution, in his opinion, Presbia’s Microlens offers an optimum balance of excellent outcomes, minimal invasiveness, and upgradability compared with other available treatments.

He noted further that Presbia’s Microlens procedure is relatively easy and quick to perform, and is also attractive to ophthalmic surgeons as it requires the same femtosecond laser used in LASIK surgery. The Microlens can also be readily replaced with a stronger lens as patients’ accommodative power changes with age.

Presbia is currently conducting a U.S. Food and Drug Administration (FDA) pivotal study of 421 subjects. All subjects recently completed their 6-month postoperative visits, a significant milestone in the FDA approval process. Concurrently the Company is pursuing its commercial strategy outside of the U.S. with a focused approach of activities taking place in South Korea, which will demonstrate the superiority, safety, and efficacy of Presbia’s Microlens technology.

Dr. Assil is a member of Presbia’s Medical Advisory Board and owns stock in the Company.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005077/en/